The characterization of an FGFR-driven subtype of CCA, most commonly caused by FGFR2 translocations resulting in constitutive downstream activation, has resulted in the emergence of FGFR inhibitors as a viable treatment option in advanced and metastatic CCA. This evidence concerns the gene FGFR2 and cholangiocarcinoma.